Get access

Should intravenous immunoglobulin be used in infants with isoimmune haemolytic disease due to ABO incompatibility?

Authors

  • Amy K Keir,

    Corresponding author
    1. Division of Neonatology, Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
    2. School of Paediatrics and Reproductive Health, University of Adelaide, South Australia, Australia
    • Correspondence: Dr Amy Keir, Division of Neonatology, The Hospital for Sick Children, 555 University Avenue, Toronto, ON, Canada M5G 1X8. Fax: +1 (416) 813-5245; email: amy.keir@sickkids.ca

    Search for more papers by this author
  • Michael Dunn,

    1. Division of Neonatology, Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada
    Search for more papers by this author
  • Jeannie Callum

    1. Department of Laboratory Medicine and Pathobiology Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
    2. Department of Clinical Pathology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Search for more papers by this author

Abstract

Abstract

The use of intravenous immunoglobulin in isoimmune haemolytic disease due to ABO incompatibility is recommended by the American Academy of Pediatrics and the National Blood Authority, Australia. However, the evidence these recommendations are based on appears limited and, in some instances, outdated. In our article, we review the current available literature to help answer the question, ‘In infants with isoimmune haemolytic disease due to ABO incompatibility [P], does use of intravenous immunoglobulin and intensive phototherapy [I] compared with intensive phototherapy alone [C] provide any clinically important benefits [O]?’

Ancillary